Fisher & Paykel Healthcare Corporation Limited advises that the company’s results for the year ended 31 March 2020 will be released on Monday, 29 June 2020, instead of Thursday, 28 May 2020, as previously advised.
This announcement has been made in reliance on the NZX class waiver dated 19 March 2020, which provides listed companies with an additional 30 days to prepare and release their full year results, and an additional two months to prepare and deliver their annual reports.
Fisher & Paykel Healthcare Corporation Limited intends to release its annual report together with its financial results on Monday, 29 June 2020 and, accordingly, as at the date of this announcement, does not intend to rely on the NZX class waiver with respect to the publication of its annual report.
“At the present time, we have nearly 5,000 people around the world who are focussed on meeting the increased demand for our respiratory products, which are being used in the treatment of patients with COVID-19,” said Chief Financial Officer Lyndal York.
“This time of year our financial controllers in our global offices would usually be dedicated to completing year end reporting. Because of the COVID-19 pandemic, many of these people are currently working remotely – assisting with customer enquiries, getting product into the hands of customers and providing operational support.”
“One of our core beliefs is doing what is best for the patient, and it should come as no surprise that we think that these activities should take priority,” said Mrs York.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Investor Relations Manager
+64 (0) 27 807 8073
Senior Communications Manager
+64 (0) 21 713 911
Fisher & Paykel Healthcare updates release date for full year results
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Providing Optimal Humidity for intubated patients
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment